Baxter buys drug-delivery specialist for $380M; Analyst highlights pair of HepC drug developers;

@FierceBiotech: Report: Samsung to test genomic analysis service. Item | Follow @FierceBiotech

@JohnCFierce: FDA approves Firazyr (Shire) for HAE. News | Follow @JohnCFierce

@RyanMFierce: Furiex Pharmaceuticals snags $15M loan to advance pipeline, including antibiotic, IBC drug and statin Article | Follow @RyanMFierce

@MaureenFierce: HPV Vaccination Rates Low Among Teen Girls, CDC Reports. Story | Follow @MaureenFierce

> Baxter International said that it plans to buy drug-delivery specialist Baxa for $380 million in cash. Article

> In its financial report for the first half of 2011, Belgium-based Ablynx ($ABLX) said it had 7 of its Nanobody drugs, which are antibody-derived protein therapeutics, in Phase I and Phase II clinical trials. Item

> Robert W. Baird analyst Thomas Russo advises investors to take a look at two up-and-coming developers of hepatitis C treatments, Achillion Pharmaceuticals ($ACHN) and Inhibitex ($INHX). Report

Pharma News

@FiercePharma: Merck's discount offer to NICE wins OK for anti-TNF drug Simponi. Piece | Follow @FiercePharma

> Cipla eyes alliances to grow in emerging markets. Story

> 'Rogue' Seroquel found in OTC painkiller packs. More

> HPV vax uptake grows, but not fast enough for CDC. Article

And Finally... Amgen ($AMGN) is teaming up with actress Blythe Danner, who has postmenopausal osteoporosis, to boost awareness of the condition. Item

Suggested Articles

Smaller biotechs are continuing their biopharma hiring spree as two startups nab some big names for their aspiring cancer drug research.

In a 7-2 vote, an FDA panel backed Aimmune’s peanut allergy treatment for approval. It desensitizes patients with increasing doses of peanut protein.

In a phase 1 trial of Atara's T-cell therapy for MS, patients who received the highest of the two doses reported showed an improvement in symptoms.